Moderna Some Approvals Ahead: Is the Stock a Buy?
Moderna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
When faced with unexpected expenses, prioritize essentials, tap your emergency buffers, and reallocate discretionary funds. A clear action plan minimizes impact fast.
9,452 articlesModerna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
Oil prices drop to a three-month low following news of a Trump Iran framework, signaling potential relief for inflati...
Nuclear power is staging a comeback, and it could reshape how you invest in utilities. This guide breaks down why the...
North America’s World Cup kickoff puts press freedom under the spotlight. CPJ warns that cpj: press freedom must endu...
Goldfinch outlines a phased wind-down of its Prime unit, shifting from growth to borrower recoveries and testing whet...
In a surprise move, President Trump said he would not sign the housing bill until Congress passes a separate voter-id...
A surge in viral public whale liquidations on Hyperliquid is turning whale activity into a real-time trading signal, ...
Geopolitical tensions around Iran are pushing oil volatility and, in turn, accelerating EV adoption. Analysts warn th...
Tesla has fallen about 14% this year, but a dip isn’t a doom signal. Here’s a clear framework to decide if now is the...
A Florida couple filed suit against Compass over a $475 closing fee, arguing the charge was undisclosed and improper,...
After years of setbacks, Intel appears to be turning a corner on its AI ambitions. This article breaks down what to w...
As AI accelerates, tech’s demand uninterrupted power is forcing investors to rethink NextEra Energy’s renewables-led ...